



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 6341

Title: Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease – a review of the literature.

Reviewer code: 01047605

Science editor: Wen, Ling-Ling

Date sent for review: 2013-10-16 09:04

Date reviewed: 2014-01-03 19:55

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> [Y] Accept
<input type="checkbox"/> [Y] Grade B (Very good)	<input type="checkbox"/> [Y] Grade B: minor language polishing	<input type="checkbox"/> [] Existed	<input type="checkbox"/> [] High priority for publication
<input type="checkbox"/> [] Grade C (Good)	<input type="checkbox"/> [] Grade C: a great deal of language polishing	<input type="checkbox"/> [] No records	<input type="checkbox"/> [] Rejection
<input type="checkbox"/> [] Grade D (Fair)	<input type="checkbox"/> [] Grade D: rejected	<input type="checkbox"/> [] Existed	<input type="checkbox"/> [] Minor revision
<input type="checkbox"/> [] Grade E (Poor)		<input type="checkbox"/> [] No records	<input type="checkbox"/> [] Major revision

COMMENTS TO AUTHORS

This is a short and well performed review. The title reflects the content. For the readers this text gives a good overview. P. 7 line 12: Would it be better to write: "... has been widely debated.."? And: I suggest that the authors comment more on the topic surveillance in non-IBD PSC.



Baishideng Publishing Group Co., Limited

Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 6341

Title: Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease – a review of the literature.

Reviewer code: 02545518

Science editor: Wen, Ling-Ling

Date sent for review: 2013-10-16 09:04

Date reviewed: 2014-01-08 04:50

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This interesting review presents a good analysis about Primary sclerosing cholangitis (PSC) as an independent risk factor for colorectal cancer (CRC) in the context of inflammatory bowel disease (IBD). However, although the authors give a thorough review up to the year 2012, they miss the most recent developments, which are very important. Major comments: 1) The authors must add the most recent developments among which two recent meta-analyses concerning the use of ursodeoxycholic acid (UDCA) as a precaution to CRC patients suffering from PSC. Thus, they must add the following papers to their review: (a) Singh S, Khanna S, Pardi DS, Loftus EV Jr, Talwalkar JA. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. *Inflamm Bowel Dis* 2013; 19:1631-1638. (b) Hansen JD, Kumar S, Lo WK, Poulsen DM, Halai UA, Tater KC. Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis. *Dig Dis Sci* 2013; 58:3079-3087. 2) They must also comment on the Mayo Clinic meta-analysis which proposes Aggressive colonoscopic surveillance for CRC in patients with PSC-IBD after liver transplantation (Singh S, Varayil JE, Loftus EV Jr, Talwalkar JA. Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: A systematic review and meta-analysis. *Liver Transpl* 2013 In Press)